Dr. Sokol received her medical degree from the University of Illinois School of Medicine in 2007, prior to completing her Pediatrics residency at the University of Chicago/Comer Children's Hospital. She completed a fellowship in Pediatric Hematology/Oncology in 2017 before completing a post-doctoral program in clinical pharmacology and pharmacogenomics in 2018 at University of Chicago. Dr. Sokol subsequently became a member of the Pediatric Hematology/Oncology division at Ann & Robert H. Lurie Children's Hospital of Chicago in September 2018.
Dr. Sokol's research interests involve the study of pediatric patients with neuroblastoma. As a member of the Children's Oncology Group's Neuroblastoma Committee, she participates in the development of new therapeutic clinical trials for patients with high risk disease. She serves as the Children's Oncology Group Pediatric Early Phase Clinical Trial Network site PI, bringing early phase trial opportunities to patients with relapsed or refractory disease. In addition, Dr. Sokol has worked with the Lurie Children's pharmacogenomic steering committee to increase utilization of pharmacogenomic testing to optimize drug utilization for patients with complex pharmacology needs.
Dr. Sokol's clinical focus centers on the treatment of pediatric solid tumor patients, including those with neuroblastoma, sarcomas, rare tumors, renal tumors, liver tumors, and germ cell tumors. Through her work with the Children's Oncology Group's Neuroblastoma Committee, she participates in the development of new therapeutic clinical trials for neuroblastoma patients.